Group B Streptococcus (GBS): Vaccine and Challenges underway

Group B Streptococcus (GBS) is a main motive of maternal, Fetal, and neonatal morbidity and mortality worldwide, related with 3.5 million preterm births, 319 zero neonatal infections, and 147 zero neonatal deaths annually. Asymptomatic anovaginal colonization of pregnant female is the most important danger aspect for neonatal GBS infections, which are normally derived from vertical transmission. An estimated 18% of pregnant female global are asymptomatically colonized by means of GBS, however this charge varies from 10% to 40% in accordance to the country